Dr. Men is the CMO of Haichang Biotech. Prior to joining Haichang, she served as a master reviewer and team leader in the Clinical Pharmacology Office, CDER FDA since 2003 with the responsibility of reviewing IND/NDA/BLA for oncology and neurological new drugs. She has received numerous awards from the FDA, including the Distinguished Service Award, Outstanding Mentor Award, Outstanding Leadership Award and Outstanding Regulatory Science Award, etc. She has actively organized and presented in various workshops and seminars at the national and international conferences. In May 2022, Dr. Men was selected into the IFPMA ICH E21 expert working group. Currently, she serves as President-elect and the board member of the Chinese Biopharmaceutical Association – USA; Ex-Vice President and board member of FDA Chinese Experts Club; Assistant Chair for the Membership and Community Outreach in Federal Asian Pacific American Council (FAPAC) and a member of China Pharmaceutical Innovation and Research Development Association. Dr. Men received her PhD in pharmaceutical sciences from Virginia Commonwealth University. Before that, she was a clinical neurologist with a medical degree from Tianjin Medical University.
Angela Yuxin Men
